anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Carboplatin
Trial phase: Phase 4
ATC code: L01XA02
SMILES: [H]N([H])([H])->[Pt]1(<-N([H])([H])[H])OC(=O)C2(CCC2)C(=O)O1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:

First hour - Administer 1 percent of total dose (5ml with tubing primed)
Second hour - Administer 9 percent (45 mL)
Third hour - Administer 90 percent (450 mL)

Carboplatin
Eligibility criteria:
Inclusion Criteria:

Participants must have histologically or cytologically confirmed ovarian cancers for which carboplatin is an acceptable treatment option. In addition, participants must be candidates for systemic chemotherapy as determined by their treating physician.
Participants must have received a carboplatin-containing regimen at initial diagnosis. Retreatment is permitted in second or greater line with carboplatin-based chemotherapy.
Age ≥ 18 years of age
Eastern Cooperative Oncology Group performance status <2 (see Appendix A).
Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to initiating chemotherapy on trial and must agree to practice an effective method of birth control, such as an intrauterine device, tubal ligation, or oral contraceptives, during the study and for six months after their last treatment. Women should not breast-feed while on this study
Ability to understand and the willingness to sign a written informed consent document
Patients must be willing to comply with study design and requirements for participating on the study.
Laboratory Criteria for eligibility The following are laboratory criteria for baseline absolute neutrophil count, platelet count, and creatinine for inclusion on this study.

Exclusion Criteria:

Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections

Ozurdex: intravitreal steroid
Eligibility criteria:
Inclusion Criteria:

Male of female age 18 years or older
Type 1 or Type 2 diabetes
Best corrected visual acuity (BCVA) score of >24 and <78 letters
History of at least 3 anti-VEGF intravitreal injections over the past 5 months
Presence of macular edema defined as central subfield thickness of >340 microns on Cirrus OCT

Exclusion Criteria:

Anti-VEGF intravitreal treatment in the last 4 weeks
Intravitreal steroid treatment in the last 8 weeks or Ozurdex in the last 4 months
Pan retinal photocoagulation (PRP) or focal laser in the last 4 months
Active iris neovascularization
Any ocular condition in the study eye that, in the opinion of the investigator, is severe enough to compromise the study result
Uncontrolled systemic disease
Known history of intraocular pressure (IOP) elevation in response to corticosteroid treatment, that is not controlled on 2 glaucoma medications
Current enrollment in an investigational drug study or participation in such a study within 30 days prior to the baseline visit
Female patients who are pregnant, nursing or planning a pregnancy or who are of childbearing potential and not using a reliable means of contraception
Any condition or reason (including inability to read early treatment diabetic retinopathy study (ETDRS) chart or language barrier) that precludes the patient's ability to comply with study requirements including completion of the study
Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
Aphakia or pseudophakia with anterior chamber intraocular lens
Hypersensitivity to any components of Ozurdex or Avastin
Intervention: Triheptanoin
Trial phase: Phase 2
ATC code: A16AX17
SMILES: CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Naïve to triheptanoin

Triheptanoin: Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).

Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.
Eligibility criteria:
Inclusion Criteria:

Individuals eligible to participate in this study must meet all of the following criteria:

Patients with GLUT1 DS by physician diagnosis
Males and females, aged 1 to 50 years
Allowed to be on concomitant AEDs
Patients are able to tolerate triheptanoin if they have been (or are currently being) treated with this medication
Must, in the opinion of the investigator, be willing and able to comply with study procedures and schedule
Provide written assent (if appropriate) and written informed consent by a Legally Authorized Representative (LAR) after the nature of the study has been explained, and prior to any research-related procedures
Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study
Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study

Exclusion Criteria:

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

Patients and their Legally Authorized Representatives (as appropriate) not willing or able to give written or verbal assent or written informed consent.
Concomitant administration of a ketogenic diet for the treatment of GLUT1 deficiency
Concomitant administration of valproic acid
In the Investigator's opinion, the patient may not be compliant
Pregnant or breastfeeding an infant at screening
Has a concurrent disease or condition, or laboratory abnormality that, in the view of the Investigator, places the subject at high risk for adverse events, or introduces additional safety concerns
History of or current suicidal ideation, behavior and attempts
Patient qualifies for any other clinical trial designed to progressively evaluate the safety and efficacy of triheptanoin as approved by the FDA under a separate IND which is open at Cook Children's
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.

Bupivacaine: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18, who are to undergo sacrospinous ligament colpopexy for vaginal apex prolapse after hysterectomy
Other concomitant prolapse and anti-incontinence procedures (e.g., anterior colporrhaphy, paravaginal defect repair, posterior colporrhaphy, or mid-urethral sling procedures) will be performed at the primary surgeon's discretion

Exclusion Criteria:

Inability to comprehend written and/or spoken English
Inability to provide informed consent
Need for concomitant surgeries not related to pelvic organ prolapse or incontinence
Chronic pain conditions (e.g., fibromyalgia, myositis, myofascial pain syndrome)
Intervention: Conferon
Trial phase: Phase 2
SMILES: O=S(=O)(O)O.[Fe]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 74
Group description: Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.

Intravaneous iron(low molecular weight iron dextran): 1000 mg of Iron dextran administered over one hour
Eligibility criteria:
Inclusion Criteria:

pregnant women intolerable to oral iron. hbg <10.9 g/dl during second or third trimester.

Exclusion Criteria:

known sensitivity to IV iron. hemoglobinopathies. hemolytic anemia. women who have received or will receive blood transfusions. women with significant vaginal bleeding(>200 cc blood loss)prior to delivery. women with documented history of allergy to more than one class of drug clinically significant anemia requiring therapy in the opinion of the obstetrician, in the first trimester.
Intervention: Allopurinol
Trial phase: Phase 2 | Phase 3
ATC code: M04AA01 | M04AA51
SMILES: Oc1ncnc2[nH]ncc12
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 99
Group description: Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 2-4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.

The subjects will be randomized to receive allopurinol as urate lowering therapy (ULT), at a daily dose of 300 mg once daily by mouth.
Eligibility criteria:
Inclusion Criteria:

Pre-hypertension or stage I hypertension, defined as the following after the mean of two clinic measurements:
Systolic blood pressure (SBP) ≥ 120 and <160 or;
Diastolic blood pressure (DBP) ≥ 80 and < 100
Serum urate ≥ 5.0 mg/dL for men or ≥ 4.0 mg/dL for women
Age 18-40

Exclusion Criteria:

Any current pharmacological treatment for hypertension, including diuretics (calcium channel blockers at stable doses were later allowed)
Estimated glomerular filtration rate < 60 mL/min/1.73m2
Current use of any urate-lowering therapy or statins
Prior diagnosis of gout or past use of urate-lowering therapy for gout
Prior diagnosis of diabetes
Pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3 months
Active smokers
Immune-suppressed individuals including transplant recipients or current use of azathioprine.
Leucopenia with absolute white cell count < 3000 /mL, anemia with hemoglobin < 12 g/dL, or thrombocytopenia with platelet count < 150,000/mL
Individuals of Han Chinese or Thai descent with HLAB5801 genetic phenotype
Serious medical condition that at investigator's judgment precludes utilization of a fixed dose of allopurinol
Intervention: METHYLPREDNISOLONE ACETATE
Trial phase: Phase 4
SMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 116
Group description: Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)

Depo-Medrone: Steroid Injection
Eligibility criteria:
Inclusion Criteria:

Male or female aged ≥ 18 years
A clinical diagnosis of unilateral or bilateral CTS as made by a GP or trained clinician according to the diagnostic criteria
Mild (e.g. intermittent paraesthesia) or moderate (e.g. constant paraesthesia, reversible numbness and / or pain) severity CTS of idiopathic nature
Symptom duration of episode of at least 6 weeks
Written informed consent provided by the patient, prior to any trial specific procedures

Exclusion Criteria:

Steroid injection or night splints for CTS in the affected wrist within preceding 6 months
Any previous surgery on the affected wrist
Severe CTS exhibiting constant numbness or pain, constant sensory loss, severe thenar muscle atrophy or symptom severity which requires the patient to be referred for a surgical opinion
Clinical suspicion of local or systemic sepsis or infection
Current or previous infection of the affected wrist
Trauma to the affected hand requiring surgery or immobilisation in the previous 12 months
Unable to tolerate the study interventions
Unable to understand and complete self-report questionnaires written in English

Inter-current illness including, but not limited to:

poorly controlled thyroid disease
poorly controlled diabetes mellitus
vibration-induced neuropathy
inflammatory joint disease
suspected complex neurological conditions
any other severe medical illness which in the opinion of the local Principal Investigator (or other authorised clinical delegate) precludes trial participation
Pregnant or lactating females
Receiving anticoagulants
Any history of hypersensitivity to Depo-Medrone or any of its excipients
Allergy to any of the splint materials
Known abuse of drugs or alcohol
Involved in on-going litigation cases for their condition
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Corticosteroid injection (betamethasone) without ultrasound guidance.

Betamethasone
Eligibility criteria:
Inclusion Criteria:

Pain with palpation at 1st dorsal compartment at wrist and positive Finkelstein's Test

Exclusion Criteria:

Patients with evidence of osteoarthritis or degeneration of the wrist.
Intervention: Prednisone
Trial phase: Phase 4
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.

prednisone: 6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed Barretts mucosa with high grade dysplasia or early esophageal adenocarcinoma (T1a, intramucosal adenocarcinoma).
Barretts segment ≥ 30% circumference, ≤C3 and ≤M5.
The general health condition of the patient permits anesthesia for endoscopy.
Patient is 18 years of age or older.
Informed consent is obtained

Exclusion Criteria:

Previous (referral) biopsies show low grade dysplasia only, or invasive adenocarcinoma.
Barretts segment <30% circumference, >C3 or >M5.
During initial gastroscopy there are highly suspicious areas for submucosal invasive cancer (Kudo pit pattern type V; excavated/depressed type morphology; large smooth or ulcerated nodule). In cases of significant doubt, initial resection is of the highly suspicious area only, and urgent histology processing requested. If submucosal invasion is excluded, the patient is rebooked for 1st stage complete barrett's excision (60% circumferential resection) and randomization after a 4-6 weeks interval.
Presence of a tight peptic oesophageal stricture that impedes safe and effective endoscopic mucosal resection using a cap (Cook Medical).
Active malignancy, uncontrolled Diabetes Mellitus, active or untreated major psychiatric disorder, uncontrolled infection, uncontrolled hypertension, uncontrolled or severe congestive cardiac failure, non-correctable coagulopathy (INR>2, or platelet count <60 x 109/L), osteoporosis, recent peptic ulcer disease, moderate-to-severe glaucoma or untreated glaucoma, or pregnancy.
Unable to provide informed consent
Allergy to compound used in tablet formulation
Intervention: Ketorolac
Trial phase: Not Applicable
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 192
Group description: Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery

Ketorolac: ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
Eligibility criteria:
Inclusion Criteria:

American society of Anesthesiologists(ASA) physical status 1 and 2
20-60 years old female
elective scheduled thyroidectomy

Exclusion Criteria:

surgery longer than 3 hours Previous history of or expected difficult tracheal intubation Laryngoscope grade (by Cormack and Lehane) of 3 or 4 2 more trial for intubation BMI > 30 Hypersensitivity to ketorolac history of asthma respiratory tract infection during the past 6 weeks Renal dysfunction (creatinine > 1.5 mg/dl or oligouria) Hepatic dysfunction (ALT :> 50% more than normal value) Use of corticosteroid, NSAIDS, angiotensin converting enzyme in 10 days Medication for gastritis, gastric ulcer Upper gastrointestinal bleeding history Diabetes mellitus
Intervention: Ketorolac
Trial phase: Not Applicable
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 192
Group description: Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery

Ketorolac: ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
Eligibility criteria:
Inclusion Criteria:

American society of Anesthesiologists(ASA) physical status 1 and 2
20-60 years old female
elective scheduled thyroidectomy

Exclusion Criteria:

surgery longer than 3 hours Previous history of or expected difficult tracheal intubation Laryngoscope grade (by Cormack and Lehane) of 3 or 4 2 more trial for intubation BMI > 30 Hypersensitivity to ketorolac history of asthma respiratory tract infection during the past 6 weeks Renal dysfunction (creatinine > 1.5 mg/dl or oligouria) Hepatic dysfunction (ALT :> 50% more than normal value) Use of corticosteroid, NSAIDS, angiotensin converting enzyme in 10 days Medication for gastritis, gastric ulcer Upper gastrointestinal bleeding history Diabetes mellitus
Intervention: Clemastine
Trial phase: Phase 2
ATC code: D04AA14 | R06AA04 | R06AA54
SMILES: CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Participants received Clemastine 4mg twice daily for either 3 months or 2 months.
Eligibility criteria:
Inclusion Criteria:

Relapsing remitting Multiple Sclerosis by 2010 Revised McDonald Criteria
Age 18-60.
Latency delay > 125 milliseconds on baseline full-field transient pattern reversal visual evoked potential (VEP) in at least one eye (electrophysiological evidence of demyelination)
Retinal nerve fiber layer (RNFL) > 70 microns on Spectralis Domain Optical Coherence Topography (SD-OCT) in the same eye meeting criteria for latency delay (sufficient axons)
No optic neuritis in prior 6 months
Stable immunomodulatory therapy - no switch or planned switch in > 6 months and no change in doses in 30 days prior to screening
Use of appropriate contraception during period of trial (females of child bearing potential)
Understand and sign informed consent.
Expanded disability status scale (EDSS) 0-6.0 (inclusive)

Exclusion Criteria:

Major ophthalmologic disease / Concomitant ophthalmologic disorders (e.g. diabetes, macular degeneration, glaucoma, severe myopia , etc).
Myopia > -7 Diopters (Severe myopia)
History of significant cardiac conduction block
History of cancer
Known optic neuritis in involved eye > 5 years ago OR disease duration > 15 years
Suicidal ideation or behaviour in 6 months prior to screening
Pregnancy, breastfeeding, or planning to become pregnant.
Involved with other study protocol simultaneously without prior approval. 9. Concomitant use of Dalfampridine (4AP or diamino4AP) or any other formulation of 4AP or diamino4AP.
Concomitant use of any other putative remyelinating therapy as determined by investigator.
Treatment with corticosteroids within 30 days prior to screening
Prior treatment with total lymphoid irradiation, T cell or T cell receptor vaccination
Prior treatment with alemtuzumab, mitoxantrone, or cyclophosphamide
Serum creatinine > 1.5 mg/dL; aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase > 2 times the upper limit of normal
History of drug or alcohol abuse within the past year
Untreated vitamin B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid (MMA) and homocysteine) or untreated hypothyroidism
Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, psychiatric allergic, renal or other major diseases that in the PI's judgment may affect interpretation of study results or patient safety.
History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study
Intervention: Revefenacin
Trial phase: Phase 2
ATC code: R03BB08
SMILES: CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 68
Group description: TD-4208

TD-4208
Eligibility criteria:
Inclusion Criteria:

Subject is a male or female subject 40 years of age or older
Subject must have a negative pregnancy test, and must be prepared to use effective contraception if of child-bearing potential
Subject is capable of performing reproducible spirometry maneuvers
Subject has post-bronchodilator FEV1/FVC ratio <0.7
Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD Guidelines)
Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80% of predicted normal
Subject has a current or past smoking history of at least 10 pack-years.

Exclusion Criteria:

Subject has a significant respiratory disease or disorder other than COPD that would affect the interpretation of data from this study
Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergic or beta-agonist agents
Subject suffers from any medical condition that would preclude the use of inhaled anticholinergic agents
Subject has been hospitalized for COPD or pneumonia within 12 weeks
Subject requires long-term oxygen therapy (>15 hours a day)